-
Featured Authors
-
Archives
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: Tracy Cooley
Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.
Latest Posts
Exploring New Solutions For Neglected Diseases in Developing Countries
On Tuesday, BIO Ventures for Global Health (BVGH) announced the completion of the 30th research agreement as part of its partnership with the World Intellectual Property Organization (WIPO) to better enable drug companies to assist researchers in addressing infectious diseases worldwide. The partnership aims to accelerate development of drugs, diagnostics and vaccines for more than 1.5 billion people suffering from malaria, tuberculosis, and other neglected tropical diseases including dengue in developing nations. A recent publication in Read More >
BioCentury This Week: Death & Taxes – Startups Need Fixes
Vitae CEO Jeff Hatfield, Ernst & Young Partner Christopher Ohmes, and GPB Scientific CEO Michael Grisham will be discussing proposed tax changes that could spur billions of dollars in investment and create hundreds of thousands of jobs on BioCentury This Week airing Sunday September, 15 at 8:30am EST on WUSA-9. Biotech startups face death before taxes and unless investors are willing to finance years of losses, technologies that could save and improve lives are left Read More >
E&Y Study: 3 Tax Tweaks that Could Spur Job Growth
A new report from Ernst & Young illustrates the economic impact of three tax proposals intended to help small businesses spur innovative research and development. The report indicates that the three tax revisions, if enacted together, could drive up research and development investments by more than $20 billion and create an estimated 623,000 new jobs at new and small firms. The report outlines the potential impact of the three proposals, which include: The R&D partnership Read More >
New PhRMA Report: Nearly 300 Vaccines Currently in Development
Today, the Pharmaceutical Research and Manufacturers of America released a report, Medicines in Development: Vaccines – A Report on the Prevention and Treatment of Disease Through Vaccines. The report shows that U.S. biopharma companies are currently developing 271 vaccines to prevent and treat numerous conditions, including infectious diseases and various forms of cancer and neurological disorders. Vaccines have successfully prevented devastating infectious diseases such as smallpox, measles and polio. According to data from the Centers Read More >
New FDA Final Guidance on Clinical Trial Institutional Review Boards
On Tuesday, August 27th, the FDA finalized its Guidance for Institutional Review Boards, Clinical Investigators and Sponsors on Institutional Review Board Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an Investigational New Drug/Investigational Device Exemption is Needed. In an article published earlier today, the Pink Sheet’s Sarah Karlin summarized the goals of this guidance as strengthening human subject protection during clinical research and increasing the efficiency of Read More >
